Biomarin Pharmaceutical Inc BMRN:NASDAQ

Last Price$84.68NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/02/21

Today's Change+0.18(0.21%)
Bid (Size)$82.24 (1)
Ask (Size)$86.66 (4)
Day Low / High$84.15 - 85.89
Volume990.1 K
 

View Biotechnology IndustryPeer Comparison as of 12/02/2021

 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $84.68
Change: +0.18 (0.21%)
Volume: 990.1 K
4:00PM ET 12/02/2021
 
 

Repligen Corp ( NASDAQ )

Price: $268.82
Change: -8.02 (2.90%)
Volume: 324.6 K
4:00PM ET 12/02/2021
 
 

Novavax Inc ( NASDAQ )

Price: $161.97
Change: -30.68 (15.93%)
Volume: 9.2 K
4:00PM ET 12/02/2021
 
 

Incyte Corp ( NASDAQ )

Price: $66.63
Change: +1.67 (2.57%)
Volume: 2.4 M
4:00PM ET 12/02/2021
 
 

Exact Sciences Corp ( NASDAQ )

Price: $80.57
Change: +0.29 (0.36%)
Volume: 1.6 M
4:00PM ET 12/02/2021
 

Read more news Recent News

Credit Suisse Raises BioMarin Pharmaceutical's PT to $105 from $100 After VOXZOGO Gets FDA Approval; Keeps Outperform Rating
11:01AM ET 11/22/2021 MT Newswires

BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $84 to $173, according to analysts polled by Capital IQ....

--Goldman Sachs Adjusts Price Target for BioMarin Pharmaceutical to $173 From $169, Maintains Buy Rating
9:40AM ET 11/22/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Baird Adjusts Price Target for BioMarin Pharmaceutical to $112 From $101, Maintains Outperform Rating
9:38AM ET 11/22/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

JPMorgan Adjusts BioMarin Pharmaceutical's Price Target to $135 From $129, Maintains Overweight Rating
9:37AM ET 11/22/2021 MT Newswires

BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $84 to $173, according to analysts polled by Capital IQ....

Company Profile

Business DescriptionBioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA. View company web site for more details
Address770 Lindaro Street
San Rafael, California 94901
Phone+1.415.506.6700
Number of Employees2,849
Recent SEC Filing12/02/20214
Chairman & Chief Executive OfficerJean-Jacques Bienaimé
Chief Financial Officer & Executive Vice PresidentBrian R. Mueller
Chief Information OfficerEduardo E. von Pervieux
President-Worldwide Research & DevelopmentHenry J. Fuchs

Company Highlights

Price Open$84.93
Previous Close$84.68
52 Week Range$71.59 - 92.57
Market Capitalization$15.5 B
Shares Outstanding183.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings1.1K
Earnings per Share$0.10
Beta vs. S&P 500N/A
Revenue$1.5 B
Net Profit Margin0.86%
Return on Equity0.38%

Analyst Ratings as of 11/19/2021

Buy
16
Overweight
3
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset